Publications

Found 88 Publications

BIOLOGICAL MARKERS FOR IDENTIFYING IBRUTINIB RESISTANCE IN PATIENTS HAVING MANTLE CELL LYMPHOMA AND METHODS OF USING THE SAME

Disclosed herein are methods of predicting a likelihood of responsiveness to treatment with ibrutinib in a patient having mantle cell lymphoma and methods of treating a patient having mantle cell…


Leveraging transcriptomic and genomic data to better select models for preclinical oncology therapeutic development to identify cell lines most similar to patient tumors

Cancer cell lines represent the front line of new compound testing, and results from these experiments often decide which compounds go on for further testing. Genomic context plays a critical…


Leveraging public genomic data to accelerate oncology therapeutic development in pancreatic cancer.

Pancreatic cancer has an estimated survival rate of only 5-6% (Siegel et al. 2015). The difficulty in early detection methods compounded by clinical trial failures precipitates the need for innovative…


Serum Proteomic Analysis of Multiple Myeloma Subjects Treated with Daratumumab Monotherapy

Daratumumab (DARA) is a human IgG1κ monoclonal antibody that binds with high affinity to a unique epitope on CD38. DARA monotherapy has shown promising activity in relapsed and/or refractory multiple…


Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition

Glatiramer acetate (Copaxone®; GA) is a non-biological complex drug for multiple sclerosis. GA modulated thousands of genes in genome-wide expression studies conducted in THP-1 cells and mouse splenocytes. Comparing GA…

Journal: Journal of Neuroimmunology


Accelerating pancreatic cancer drug screening by leveraging genomics to select better in vitro models.

Cell lines used for pre-clinical testing of oncology compounds are not always chosen based on how well they models patient tumors. Instead they are often chosen based on availability and…


Leveraging existing data sets to generate new insights into Alzheimer’s disease biology in specific patient subsets

To generate new insights into the biology of Alzheimer’s Disease (AD), we developed methods to combine and reuse a wide variety of existing data sets in new ways. We first…

Journal: Scientific Reports


Improving pancreatic cancer drug discovery by leveraging genomics to select better in vitro models

Currently, pancreatic cancer has an estimated 5-year survival rate of only 5-6%. The projection that pancreatic cancer will be the second leading cause of cancer related death by 2020 compounded…


Glatiramoids

Glatiramoids are non-biologic complex drugs (NBCDs) comprising four naturally occurring amino acids in a complex copolymeric mixture. The first and most thoroughly studied glatiramoid, glatiramer acetate (Copaxone®, Teva Pharmaceutical Industries,…


Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids

Sub Title Goes Here

Journal: Scientific Reports


Page 8 of 9